GLP-1 Receptor Activation Indirectly Reduces Hepatic Lipid Accumulation But Does Not Attenuate Development of Atherosclerosis in Diabetic Male ApoE−/− Mice
The DOI matches its Crossref record; 52 of the 53 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 receptor (GLP-1R) agonists reduce lipid accumulation in peripheral tissues, attenuating atherosclerosis and hepatic steatosis in preclinical studies. We examined whether GLP-1R activation decreases atherosclerosis progression in high-fat diet-fed male ApoE(-/-) mice after administration of streptozotocin and treatment with the long-acting GLP-1R agonist taspoglutide administered once monthly vs. metformin in the drinking water for 12 wk. Taspoglutide did not reduce plaque area or lipid content in the aortic arch or abdominal aorta, and no significant change in aortic macrophage accumulation was detected after taspoglutide or metformin. In contrast, hepatic triglyceride levels were significantly reduced in livers from taspoglutide-treated mice. Both peripheral and intracerebroventricular administration of exendin-4 rapidly decreased plasma triglyceride levels in fasted mice, and taspoglutide therapy in ApoE(-/-) mice modulated the expression of hepatic genes controlling fatty acid uptake and oxidation. We were unable to detect expression of the entire Glp1r coding sequence in macrophages isolated from ApoE(-/-), C57BL/6, and IL10(-/-) mice. Similarly, Glp1r mRNA transcripts were not detected in RNA from isolated murine hepatocytes. Using Western blotting and tissue extracts from Glp1r(+/+) and Glp1r(-/-) mice, and cells transfected with a tagged murine GLP-1R cDNA, we could not validate the sensitivity and specificity of three different GLP-1R antisera commonly used for the detection of GLP-1R protein. Taken together, these findings illustrate divergent actions of GLP-1R agonists on atherosclerosis progression and accumulation of ectopic lipid in ApoE(-/-) mice and highlight the importance of indirect GLP-1R actions for the control of hepatic lipid accumulation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Glp1r expression is undetectable by quantitative PCR in peritoneal or adipose tissue macrophages (37), although Lyz2-Cre–driven deletion of Glp1r (Glp1rLyz2–/–) abolishes expression in bone marrow–derived macrophages (38).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [37]
In the citing paper
“The limited specificity of many antibodies against mouse and human GLP-1R, combined with the challenges of detecting the receptor at low abundance, has been well documented (37, 39, 40).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [37]
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791 · cited 2×
“Histological sections were scored for hepatic lobular inflammation, ballooning, apoptosis, Kupffer cells, fibrosis, and steatosis according to guidelines set by the Pathology Committee of the NASH (nonalcoholic steatohepatitis) Clinical Research Network (25) in a blinded manner by a trained pathologist (C.”
Metabolism of Isolated Fat Cells
Rodbell, M. (1964) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)51687-2 · Cited by 4,427
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210 · cited 1×
“Two of the relatively newer classes, glucagon-like peptide-1 receptor (GLP-1R) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors, exert their glucose-lowering actions predominantly through activation of the GLP-1R (2).”
Self-citationMETABOLISM OF ISOLATED FAT CELLS. I. EFFECTS OF HORMONES ON GLUCOSE METABOLISM AND LIPOLYSIS.
Rodbell, M. (1964) · PubMed · Cited by 1,387
Insulin Resistance, Hyperglycemia, and Atherosclerosis
Bornfeldt, K. E., & Tabas, I. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.07.015 · Cited by 995 · cited 3×
“Although hyperglycemia and insulin resistance substantially accelerate the development of clinical and experimental atherosclerosis (11), whether sustained activationofGLP-1Rsignalingmightattenuate thedevelopment of atherosclerosis in the setting of insulin resistance, impairment of -cell function, and hyperglycemia r…”
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793 · cited 6×
“D PBO (14) D Met PBO (15) D TASPO (15) * * ** ***”
InfluentialSelf-citationTissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor
Bullock, B. P., Heller, R. S., & Habener, J. F. (1996) · Endocrinology · doi:10.1210/en.137.7.2968 · Cited by 618 · cited 2×
“In contrast, other investigators have failed to detect mRNA transcripts encoding a full-length Glp1r in human, rat, or mouse liver (17, 37, 47-49), and we previously reported the absence of cAMP accumulation in response to GLP-1 or exendin-4 in isolated murine hepatocytes (17).”
Noyan-Ashraf, M. H., Momen, M. A., Ban, K., Sadi, A.-M., Zhou, Y.-Q., Riazi, A. M., Baggio, L. L., Henkelman, R. M., Husain, M., & Drucker, D. J. (2009) · Diabetes · doi:10.2337/db08-1193 · Cited by 575 · cited 1×
“ocytes and exert direct effects in the cardiovascular system (3).”
Self-citationDing, X., Saxena, N. K., Lin, S., Gupta, N., & Anania, F. A. (2006) · Hepatology · doi:10.1002/hep.21006 · Cited by 557 · cited 2×
“Glp1r mRNA transcripts have been detected in human liver (38) by RT-PCR and an immunoreactive GLP-1R protein was detected in murine, rat, and human hepatocytes by Western blotting (31, 38, 41, 45).”
Arakawa, M., Mita, T., Azuma, K., Ebato, C., Goto, H., Nomiyama, T., Fujitani, Y., Hirose, T., Kawamori, R., & Watada, H. (2010) · Diabetes · doi:10.2337/db09-1694 · Cited by 548 · cited 7×
“Taspoglutide treatment of ApoE / mice The results of previous studies demonstrated that continuous GLP-1 or exendin-4 administration attenuated the development of atherosclerosis in normoglycemic ApoE / mice (7, 10).”
InfluentialGupta, N. A., Mells, J., Dunham, R. M., Grakoui, A., Handy, J., Saxena, N. K., & Anania, F. A. (2010) · Hepatology · doi:10.1002/hep.23569 · Cited by 532 · cited 3×
“Glp1r mRNA transcripts have been detected in human liver (38) by RT-PCR and an immunoreactive GLP-1R protein was detected in murine, rat, and human hepatocytes by Western blotting (31, 38, 41, 45).”
Cardiovascular Biology of the Incretin System
Ussher, J. R., & Drucker, D. J. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1052 · Cited by 530 · cited 7×
“Pl as m a IL -6 (p g/ m l) 90 80 70 60 50 40 30 20 10 0 D PBO (5) D Met PBO (4) D TASPO (4) I”
InfluentialSelf-citationYusta, B., Baggio, L. L., Estall, J. L., Koehler, J. A., Holland, D. P., Li, H., Pipeleers, D., Ling, Z., & Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.10.001 · Cited by 446 · cited 2×
“Similarly, continuous administration of native GLP-1(7-36)amide for 4 wk reduced macrophage accumulation and aortic lesion size in young nondiabetic ApoE / mice, through mechanisms sensitive to the GLP-1R antagonist exendin(9-39) (10).”
Self-citationSvegliati‐Baroni, G., Saccomanno, S., Rychlicki, C., Agostinelli, L., De Minicis, S., Candelaresi, C., Faraci, G., Pacetti, D., Vivarelli, M., Nicolini, D., et al. (2011) · Liver International · doi:10.1111/j.1478-3231.2011.02462.x · Cited by 405
Kodera, R., Shikata, K., Kataoka, H. U., Takatsuka, T., Miyamoto, S., Sasaki, M., Kajitani, N., Nishishita, S., Sarai, K., Hirota, D., et al. (2011) · Diabetologia · doi:10.1007/s00125-010-2028-x · Cited by 394 · cited 2×
“Similarly, continuous administration of native GLP-1(7-36)amide for 4 wk reduced macrophage accumulation and aortic lesion size in young nondiabetic ApoE / mice, through mechanisms sensitive to the GLP-1R antagonist exendin(9-39) (10).”
Baggio, L. L., Huang, Q., Brown, T. J., & Drucker, D. J. (2004) · Diabetes · doi:10.2337/diabetes.53.9.2492 · Cited by 386 · cited 2×
“Similarly, continuous administration of native GLP-1(7-36)amide for 4 wk reduced macrophage accumulation and aortic lesion size in young nondiabetic ApoE / mice, through mechanisms sensitive to the GLP-1R antagonist exendin(9-39) (10).”
Self-citationGlucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase
Ben-Shlomo, S., Zvibel, I., Shnell, M., Shlomai, A., Chepurko, E., Halpern, Z., Barzilai, N., Oren, R., & Fishman, S. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.09.032 · Cited by 328 · cited 2×
“Furthermore, the increase in hepatic lipase and Cpt1a expression suggests an increased ratio of fatty acids targeted toward -oxidation rather than triglyceride storage, consistent with previous findings (40, 45), whereas the decrease in 136 Panjwani et al.”
Lee, Y.-S., Park, M.-S., Choung, J.-S., Kim, S.-S., Oh, H.-H., Choi, C.-S., Ha, S.-Y., Kang, Y., Kim, Y., & Jun, H.-S. (2012) · Diabetologia · doi:10.1007/s00125-012-2592-3 · Cited by 319 · cited 2×
“Similarly, continuous administration of native GLP-1(7-36)amide for 4 wk reduced macrophage accumulation and aortic lesion size in young nondiabetic ApoE / mice, through mechanisms sensitive to the GLP-1R antagonist exendin(9-39) (10).”
Hansotia, T., Baggio, L. L., Delmeire, D., Hinke, S. A., Yamada, Y., Tsukiyama, K., Seino, Y., Holst, J. J., Schuit, F., & Drucker, D. J. (2004) · Diabetes · doi:10.2337/diabetes.53.5.1326 · Cited by 309 · cited 2×
“Body composition Total body fat and lean mass were measured using a mouse whole-body magnetic resonance analyzer (Echo Medical Systems, Houston, TX) after 5 and 10 wk of treatment as described (16).”
MethodSelf-citationLXRs regulate the balance between fat storage and oxidation
Kalaany, N. Y., Gauthier, K. C., Zavacki, A. M., Mammen, P. P. A., Kitazume, T., Peterson, J. A., Horton, J. D., Garry, D. J., Bianco, A. C., & Mangelsdorf, D. J. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.03.001 · Cited by 304 · cited 1×
“As insulinactivates theLXRpathway (46), the role of insulin as a downstream target for the effects of GLP-1R agonists on hepatic lipid metabolism requires further investigation.”
Maida, A., Lamont, B. J., Cao, X., & Drucker, D. J. (2011) · Diabetologia · doi:10.1007/s00125-010-1937-z · Cited by 294 · cited 7×
“D PBO (14) D Met PBO (15) D TASPO (15) * * ** ***”
InfluentialSelf-citationTrevaskis, J. L., Griffin, P. S., Wittmer, C., Neuschwander-Tetri, B. A., Brunt, E. M., Dolman, C. S., Erickson, M. R., Napora, J., Parkes, D. G., & Roth, J. D. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00476.2011 · Cited by 277 · cited 1×
“Sustained GLP-1R activation reduces hepatic fat accumulation, and increased hepatic lipid oxidation, reduced lipogenesis, and enhanced lipoprotein secretion have been invoked as mechanisms contributing to reduced hepatic steatosis (27, 38-42).”
Hsieh, J., Longuet, C., Baker, C. L., Qin, B., Federico, L. M., Drucker, D. J., & Adeli, K. (2010) · Diabetologia · doi:10.1007/s00125-009-1611-5 · Cited by 275
Self-citationMatsubara, J., Sugiyama, S., Sugamura, K., Nakamura, T., Fujiwara, Y., Akiyama, E., Kurokawa, H., Nozaki, T., Ohba, K., Konishi, M., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.07.053 · Cited by 273
Sharma, S., Mells, J. E., Fu, P. P., Saxena, N. K., & Anania, F. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025269 · Cited by 272 · cited 2×
“Sustained GLP-1R activation reduces hepatic fat accumulation, and increased hepatic lipid oxidation, reduced lipogenesis, and enhanced lipoprotein secretion have been invoked as mechanisms contributing to reduced hepatic steatosis (27, 38-42).”
Sauvé, M., Ban, K., Momen, M. A., Zhou, Y.-Q., Henkelman, R. M., Husain, M., & Drucker, D. J. (2010) · Diabetes · doi:10.2337/db09-0955 · Cited by 264
Self-citationNagashima, M., Watanabe, T., Terasaki, M., Tomoyasu, M., Nohtomi, K., Kim-Kaneyama, J., Miyazaki, A., & Hirano, T. (2011) · Diabetologia · doi:10.1007/s00125-011-2241-2 · Cited by 259 · cited 6×
“Taspoglutide treatment of ApoE / mice The results of previous studies demonstrated that continuous GLP-1 or exendin-4 administration attenuated the development of atherosclerosis in normoglycemic ApoE / mice (7, 10).”
InfluentialMells, J. E., Fu, P. P., Sharma, S., Olson, D., Cheng, L., Handy, J. A., Saxena, N. K., Sorescu, D., & Anania, F. A. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00274.2011 · Cited by 202 · cited 3×
“Accordingly, we next examined the consequences of taspoglutide therapy on the liver, an organ that is also highly susceptible to ectopic lipid deposition and responsive to therapy with GLP-1R agonists in clinical and experimental models of diabetes (27-29).”
Quantification of Atherosclerosis in Mice
Daugherty, A., & Whitman, S. C. (2003) · Transgenic Mouse Methods and Protocols · doi:10.1385/1-59259-340-2:293 · Cited by 179 · cited 2×
“Histological analysis The aortic root was isolated for quantification of atherosclerosis lesion size as described (24).”
Lamont, B. J., Li, Y., Kwan, E., Brown, T. J., Gaisano, H., & Drucker, D. J. (2012) · Journal of Clinical Investigation · doi:10.1172/jci42497 · Cited by 174 · cited 2×
“Similarly, continuous administration of native GLP-1(7-36)amide for 4 wk reduced macrophage accumulation and aortic lesion size in young nondiabetic ApoE / mice, through mechanisms sensitive to the GLP-1R antagonist exendin(9-39) (10).”
Self-citationDunphy, J. L., Taylor, R. G., & Fuller, P. J. (1998) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(98)00096-3 · Cited by 164 · cited 1×
“In contrast, other investigators have failed to detect mRNA transcripts encoding a full-length Glp1r in human, rat, or mouse liver (17, 37, 47-49), and we previously reported the absence of cAMP accumulation in response to GLP-1 or exendin-4 in isolated murine hepatocytes (17).”
Flock, G., Baggio, L. L., Longuet, C., & Drucker, D. J. (2007) · Diabetes · doi:10.2337/db07-0697 · Cited by 164 · cited 3×
“Hepatocytes and the nonhepatocyte fraction (17) and adipocytes and the stromal vascular fraction were separated as described (18).”
Self-citationLee, J., Hong, S.-W., Chae, S. W., Kim, D. H., Choi, J. H., Bae, J. C., Park, S. E., Rhee, E.-J., Park, C.-Y., Oh, K.-W., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031394 · Cited by 157
The effect of glucagon-like peptide 1 on cardiovascular risk
Sivertsen, J., Rosenmeier, J. B., Holst, J. J., & Vilsbøll, T. (2012) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.211 · Cited by 156 · cited 8×
“Pl as m a IL -6 (p g/ m l) 90 80 70 60 50 40 30 20 10 0 D PBO (5) D Met PBO (4) D TASPO (4) I”
InfluentialBaggio, L. L., Huang, Q., Cao, X., & Drucker, D. J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.01.017 · Cited by 137
Self-citationSamson, S. L., Sathyanarayana, P., Jogi, M., Gonzalez, E. V., Gutierrez, A., Krishnamurthy, R., Muthupillai, R., Chan, L., & Bajaj, M. (2011) · Diabetologia · doi:10.1007/s00125-011-2317-z · Cited by 110 · cited 2×
“Accordingly, we next examined the consequences of taspoglutide therapy on the liver, an organ that is also highly susceptible to ectopic lipid deposition and responsive to therapy with GLP-1R agonists in clinical and experimental models of diabetes (27-29).”
Exendin-4 modulates diabetes onset in nonobese diabetic mice
Hadjiyanni, I., Baggio, L. L., Poussier, P., & Drucker, D. J. (2008) · Endocrinology · doi:10.1210/en.2007-1137 · Cited by 110 · cited 2×
“RT-PCR analysis Mouse Glp1r mRNA analysis was performed as described (19).”
Self-citationVittone, F., Liberman, A., Vasic, D., Ostertag, R., Esser, M., Walcher, D., Ludwig, A., Marx, N., & Burgmaier, M. (2012) · Diabetologia · doi:10.1007/s00125-012-2582-5 · Cited by 97 · cited 4×
“Both GLP-1R agonists and DPP-4 inhibitors reduce lesion formation and monocyte or macrophage accumulation in the aorta of ApoE / mice (7-10); however, the majority of these experiments have been carried out in nondiabetic mice for short periods of time.”
InfluentialAviv, V., Meivar-Levy, I., Rachmut, I. H., Rubinek, T., Mor, E., & Ferber, S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.017608 · Cited by 94 · cited 1×
“In contrast, other investigators have failed to detect mRNA transcripts encoding a full-length Glp1r in human, rat, or mouse liver (17, 37, 47-49), and we previously reported the absence of cAMP accumulation in response to GLP-1 or exendin-4 in isolated murine hepatocytes (17).”
Maida, A., Hansotia, T., Longuet, C., Seino, Y., & Drucker, D. J. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.09.004 · Cited by 88
Self-citationBurmeister, M. A., Ferre, T., Ayala, J. E., King, E. M., Holt, R. M., & Ayala, J. E. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00409.2011 · Cited by 81 · cited 3×
“Because acute intracerebroventricular exendin-4 administration reduced hepatic triglyceride levels in mice under hyperinsulinemiceuglycemic clamp conditions (30), we assessed hepatic lipid secretion in high-fat-fed mice.”
Parlevliet, E. T., de Leeuw van Weenen, J. E., Romijn, J. A., & Pijl, H. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00191.2010 · Cited by 78 · cited 1×
“Our findings are in agreement with studies in high-fat-fed mice chronically infused with intracerebroventricular GLP-1 for 2 wk that also exhibited reduced plasma triglyceride levels under hyperinsulinemic-euglycemic conditions (44).”
Flamez, D., Van Breusegem, A., Scrocchi, L. A., Quartier, E., Pipeleers, D., Drucker, D. J., & Schuit, F. (1998) · Diabetes · doi:10.2337/diabetes.47.4.646 · Cited by 71
Self-citationTerasaki, M., Nagashima, M., Watanabe, T., Nohtomi, K., Mori, Y., Miyazaki, A., & Hirano, T. (2012) · Metabolism · doi:10.1016/j.metabol.2011.11.011 · Cited by 69 · cited 2×
“Comparable antiatherogenic actions have been observed after administration of DPP-4 inhibitors to ApoE / mice, findings attributable to antiinflammatory actions of GLP-1R signaling in macrophages and endothelial cells (8, 33).”
Liang, C.-P., Han, S., Li, G., Tabas, I., & Tall, A. R. (2012) · Diabetes · doi:10.2337/db11-1415 · Cited by 62 · cited 2×
“Similarly, continuous administration of native GLP-1(7-36)amide for 4 wk reduced macrophage accumulation and aortic lesion size in young nondiabetic ApoE / mice, through mechanisms sensitive to the GLP-1R antagonist exendin(9-39) (10).”
寺﨑, 道. (2012) · Medical Entomology and Zoology · Cited by 54
GLP-1 (9–36) Amide Metabolite Suppression of Glucose Production in Isolated Mouse Hepatocytes
Tomas, E., Stanojevic, V., & Habener, J. (2010) · Hormone and Metabolic Research · doi:10.1055/s-0030-1253421 · Cited by 53
Taspoglutide, an Analog of Human Glucagon-Like Peptide-1 with Enhanced Stability and in Vivo Potency
Sebokova, E., Christ, A. D., Wang, H., Sewing, S., Dong, J. Z., Taylor, J., Cawthorne, M. A., & Culler, M. D. (2010) · Endocrinology · doi:10.1210/en.2009-1459 · Cited by 51 · cited 2×
“Similarly, continuous administration of native GLP-1(7-36)amide for 4 wk reduced macrophage accumulation and aortic lesion size in young nondiabetic ApoE / mice, through mechanisms sensitive to the GLP-1R antagonist exendin(9-39) (10).”
Cardiovascular safety and diabetes drug development
Drucker, D. J., & Goldfine, A. B. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62299-4 · Cited by 37 · cited 1×
“There are no completed long-term prospective clinical studies that address whether sustained GLP-1R activation modifies the risk of developing atherosclerosis, strokes, or heart attacks in diabetic individuals (6).”
Self-citationParlevliet, E. T., der Elst, J. P. S.-V., Corssmit, E. P. M., Picha, K. M., O’Neil, K. T., Stojanovic-Susulic, V., Ort, T., Havekes, L. M., Romijn, J. A., & Pijl, H. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.144154 · Cited by 34 · cited 1×
“Chronic GLP-1R activation reduces hepatic very-low-density lipoprotein production in highfat-fed mice (43), and acute intracerebroventricular administration of GLP-1 during hyperinsulinemic-euglycemic clamp experiments rapidly reduced hepatic triglyceride content in high-fat-fed mice (30).”
Cited by
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170
“The canonical GLP-1R is not expressed in hepatocytes (Flock et al., 2007; Landgraf et al., 2015; Panjwani et al., 2013), and expression of the GLP1R within non-hepatocyte liver cell types has not been conclusively established.”
BackgroundMethodInfluentialSelf-citationGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
“A general caveat when analyzing the tissue distribution of the GLP-1R protein is the lack of sufficiently selective and commercially available antibodies [391].”
BackgroundSelf-citationPharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
“…PCR with primers that span the Glp1r coding region demonstrates that murine hepatocytes do not express full-length (1.4 kb) Glp1r mRNA transcripts (Panjwani et al., 2013), nor do they Cell Metabolism 17, June 4, 2013 ª2013 Elsevier Inc. 7 The direct and indirect actions of GIP on target tissues…”
BackgroundInfluentialSelf-citationThe Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
Pyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B. (2014) · Endocrinology · doi:10.1210/en.2013-1934 · Cited by 876
“hepatocytes in a study having rigorous controls (7).”
Background
Metadata
- Authors
- Panjwani, N., Mulvihill, E. E., Longuet, C., Yusta, B., Campbell, J. E., Brown, T. J., Streutker, C., Holland, D., Cao, X., Baggio, L. L., & Drucker, D. J.
- Affiliations
- Mount Sinai Hospital (CA)
- St. Michael's Hospital (CA)
- Corresponding author
- Drucker, Daniel J.
- ORCID
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2013-01-01
- Volume
- 154
- Issue
- 1
- Pages
- 127-139
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W1992116679
- Cited by
- 346
- References
- 53
- Citations by year
- 2026: 12 · 2025: 19 · 2024: 19 · 2023: 23 · 2022: 23 · 2021: 21 · 2020: 24 · 2019: 23 · 2018: 27 · 2017: 24 · 2016: 26 · 2015: 32 · 2014: 38 · 2013: 32
- FWCI
- 26.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- GLP-1 receptor, exendin-4, atherosclerosis, hepatic lipid accumulation, hepatic steatosis, ApoE-deficient mice, streptozotocin-induced diabetes, metformin, aortic plaque, hepatic triglycerides, fatty acid uptake, fatty acid oxidation
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Animals, Apolipoproteins E, Body Composition, Glucose Tolerance Test, Liver, Macrophages, Male, Peptides, Blotting, Western, Interleukin-10, Receptors, Glucagon, Mice, Knockout, Hepatocytes, Atherosclerosis, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.